Return Home

about IAS-USA
news and events
cme
hiv/aids
viral hepatitis course resources cases on the web
mailing list
course registration
Cases on the Web
publications/guidelines
guidelines
Pocket Cards
Webcast and Podcasts
board and staff
core faculty
fdd
donations
contact
home
clear_a

Font SizeReduce Text Size Increase Text Size

Optional method to change the font size: hold down <CTRL> and type "+" or "-"

For your convenience, we suggest that you bookmark this page. Additional meeting information will be posted to this Web site, as it is available.

main logo

Quick Links: to access program details, click on any link listed below. To return to this page, click on the back button of your browser.

SAN FRANCISCO COURSE – MONDAY, MAY 16, 2011

Course Chairs:

Robert T. Schooley, MD
Course Chair
Member, Board of Directors (Volunteer)
International Antiviral Society–USA
Professor and Vice Chair
Department of Medicine
Head, Division of Infectious Diseases
University of California San Diego
La Jolla, California

Stephen E. Follansbee, MD
Course Vice-Chair
Clinical Professor of Medicine
University of California San Francisco
Director of HIV Services
Kaiser Permanente Medical Center
San Francisco, California

COURSE OVERVIEW

Assessment of Needs:

Rapid advances in HIV disease management require the ongoing attention of practitioners involved in HIV medicine. This course will address the implications of new information on strategies for clinical management. Information will be presented through a mix of didactic lectures and clinically relevant cases developed by an expert faculty of HIV/AIDS clinicians and researchers.

Conflicts of Interest:

Information regarding financial relationships with commercial companies that have interests in the content discussed, is obtained from all parties with control over the activity content (ie, co-chairs, faculty, and IAS–USA staff), and any real or apparent conflicts of interest of those parties are resolved prior to the activity being delivered. Financial affiliations of all those parties are published in the course syllabus. Individuals who refuse to disclose financial interests may not participate in the CME activity.

Who Should Attend:

This course is designed for physicians and other clinical decision makers who are actively involved in the medical care of people with HIV/AIDS, specifically those who:

  • Have a solid, working knowledge of HIV disease management

  • Provide comprehensive or specialty care for patients with HIV/AIDS

  • Are currently active in HIV/AIDS research

This course is relevant for practitioners who are involved in HIV/AIDS patient care, including nurse practitioners and other nursing professionals, physician assistants, pharmacists, and others.

Representatives and employees of commercial companies (pharmaceutical, diagnostic, medical products, advertising, insurance, investment, communications firms, etc) must contact the IAS–USA regarding registration procedures.

GRANT SUPPORT

In the interest of an objective, balanced, and scientifically rigorous CME program, educational grants are pooled to support this activity. We gratefully acknowledge the below commercial companies for their contributions.

MAJOR SUPPORTERS:
Gilead Sciences, Inc
Merck & Co, Inc

SUBSTANTIAL SUPPORTERS:
Bristol-Myers Squibb
Tibotec Therapeutics

GENEROUS SUPPORTERS:
Abbott Laboratories
ViiV Healthcare

Requests for additional educational grants have been made to commercial companies with competing products. Information on additional grant supporters will be posted on the IAS–USA Web site as it becomes available.

AGENDA

San Francisco Course Agenda (2011) Adobe Acrobat

The agenda is updated on an ongoing basis. Please check back periodically for new information.

SYLLABUS BOOK

For syllabus book, please click here.

KEY SLIDES FROM CONFERENCE LECTURES
Conference speakers selected approximately 15 to 20 key slides from their presentations that they thought would be useful to attendees who are presenting updates from this update to their colleagues.

LEARNING OBJECTIVES

Upon completion of the course, participants will be able to:

  • Design antiretroviral strategies that consider current data on:

    • The role and use of newer approved drugs

    • Antiretroviral regimen failure

  • Explain the behavioral, epidemiologic, and virologic factors associated with sexual transmission of HIV

  • Describe the current potential for HIV eradication

  • Formulate appropriate management strategies for neurocognitive complications of HIV disease

  • Describe new data on pre-exposure prophylaxis and vaccines

  • Describe the incidence and management of dermatologic manifestations of HIV disease in dark-skinned individuals

  • Describe current data on investigational hepatitis C virus drugs as they impact the potential for treatment

CONTINUING MEDICAL EDUCATION INFORMATION

Accreditation:

The IAS–USA is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement:

The IAS–USA designates this educational activity for a maximum of 6.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Please note that nursing continuing education credits are not provided for this course. Nurse practitioners and other nursing professionals will receive a certificate of attendance.

Nursing credits are provided at selected courses. To determine if they are offered for a specific course, please click the corresponding link on the course schedule page and look under "continuing medical education information."

American Academy of Family Physicians Credit:

This activity, 19th Annual Improving the Management of HIV Disease Advanced CME Course with a beginning date of May 16, 2011, has been reviewed and is acceptable for up to 6.00 prescribed credits by the American Academy of Family Physicians.

REGISTRATION INFORMATION, DEADLINES, AND FEES

Save time and register online with secure credit card payment. You may also download and mail or fax in a completed registration form and payment.

The registration fee is $60 on or before April 25, and will increase to $80 after April 25. Early registration is strongly recommended. Preregistration closes on May 9.

Incomplete applications (missing information, unchecked boxes, no payment included) will be returned for completion, prior to processing. If you have not registered or have not received registration confirmation 2 weeks prior to the course, please contact us to confirm that seating is still available.

Representatives and employees of commercial companies (pharmaceutical, diagnostic, medical products, advertising, insurance, investment, communications firms, etc) must contact the IAS–USA regarding registration procedures.

Registered attendees may access the course syllabus, in PDF format, on our Web site after May 9. Please note: The syllabus is typically more than 100 pages long and may take extra time to download. Please submit requests for cancellation or substitution in writing to the IAS–USA office by May 2.

Contact the IAS–USA:
425 California Street Suite 1450
San Francisco, CA 94104-2120
Phone: (415) 544-9400
Fax: (415) 544-9401

Register online: https://www.iasusa.org/register.php
Download a registration form: http://www.iasusa.org/registration/form/2011/ssanfrancisco.pdf

HOTEL, TRAVEL, AND GENERAL MEETING INFORMATION

For general venue information, including directions and parking, please click here.

© Copyright 2012. International Antiviral Society–USA. All rights reserved.
Use of this site is subject to the Visitor's Agreement and Privacy and Confidentiality Policy.
Please read them carefully.

Return to Top

clear_b